Select a medication above to begin.
cyclosporine non-modified
generic
Black Box Warnings .
Appropriate Use
should only be administered by physicians experienced in immunosuppressive tx and management of organ transplant patients in adequate medical facility; physician responsible for maintenance tx should have all info needed for patient follow-up
Immunosuppressant
administer in combo with adrenal corticosteroids but no other immunosuppressants; immunosuppression incr. infection and lymphoma risks
Bioequivalence
cyclosporine non-modified formulations have decr. bioavailability vs. modified formulations; not bioequivalent, not interchangeable without physician supervision
Monitor Drug Levels
due to erratic absorption monitor drug levels regularly and adjust dose as appropriate to avoid toxicity due to high levels or organ rejection due to low levels, especially in liver transplant patients
Adult Dosing .
Dosage forms: CAP: 25 mg, 100 mg; SOLUTION: 100 mg per mL; INJ: various
Special Note
- [equivalency or interchangeability info]
- Info: modified and non-modified cyclosporine products not bioequivalent; caution advised if switching between products
organ transplant rejection prophylaxis
- [PO route]
- Dose: dosing protocols vary; Start: 15 mg/kg/dose PO x1 give 4-12h pre-transplant or postop, then 10-15 mg/kg/day PO x1-2wk, then decr. 5%/wk to 5-10 mg/kg/day PO divided bid; Info: for heart, kidney, or liver transplant; adjust dose based on target levels, rejection status, adverse effects
- [IV route]
- Dose: dosing protocols vary; Start: 5-6 mg/kg/day IV, give 1st dose 4-12h pre-transplant or postop; Info: for heart, kidney, or liver transplant; adjust dose based on target levels, rejection status, adverse effects; IV dose is 1/3 PO dose, switch to PO form ASAP
leprosy reaction, type 1 (reversal reaction), severe (off-label)
- [5 mg/kg/day PO divided qd-bid]
- Info: not 1st-line agent
renal dosing
- [transplant]
- renal impairment: no adjustment
- HD/PD: no adjustment; no supplement
- [off-label use]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- hepatic impairment: not defined, caution advised
Peds Dosing .
- Dosage forms: CAP: 25 mg, 100 mg; SOLUTION: 100 mg per mL; INJ: various
Special Note
- [equivalency or interchangeability info]
- Info: modified and non-modified cyclosporine products not bioequivalent; caution advised if switching between products
organ transplant rejection prophylaxis (off-label)
- [PO route]
- Dose: dosing protocols vary; Start: 15 mg/kg/dose PO x1 given 4-12h pre-transplant or postop, then 10-15 mg/kg/day PO x1-2wk, then decr. 5%/wk to 5-10 mg/kg/day PO divided bid; Info: for heart, kidney, or liver transplant; adjust dose based on target levels, rejection status, adverse effects
- [IV route]
- Dose: dosing protocols vary; Start: 5-6 mg/kg/day IV, give 1st dose 4-12h pre-transplant or postop; Info: for heart, kidney, or liver transplant; adjust dose based on target levels, rejection status, adverse effects; IV dose is 1/3 PO dose, switch to PO form ASAP
renal dosing
- [no adjustment]
- renal impairment: no adjustment
- HD/PD: no adjustment; no supplement
hepatic dosing
- [see below]
- hepatic impairment: not defined, caution advised